Advances in the relationship between Hashimoto's thyroiditis and thyroid cancer

doi:10.3877/cma.j.issn.1674-0793.2022.04.014

Abstract

Abstract:

Hashimoto's thyroiditis (HT), a common autoimmune disease, is characterized by pathological activation of the thyroid tissue by the immune system. Thyroid cancer (TC) is the most common malignant tumor of the endocrine system, among which papillary thyroid carcinoma (PTC) has the highest incident. In recent years, the incidence of HT combined with TC has gradually increased, attracting the researchers’ focus. The similarities in immunology, endocrinology and genetics suggest that there is a certain correlation between them. This article will review the research progress of the relationship from genetics, immunology, cell proliferation and apoptosis disorders under the background of tumor microenvironment to understand the potential associations, providing new and more effective treatment strategies.

Key words: Hashimoto's thyroiditis, Thyroid neoplasms, Tumor microenvironment

Lei Li, Siqian Cui, Huiqiang Zhang, Fang Zhao, Jing Liu. Advances in the relationship between Hashimoto's thyroiditis and thyroid cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2022, 16(04): 308-312.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2022.04.014

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2022/V16/I04/308

References 36

[1]	Resende de Paiva C, Grønhøj C, Feldt-Rasmussen U, et al. Association between Hashimoto's thyroiditis and thyroid cancer in 64,628 patients[J]. Front Oncol, 2017, 7: 53.
[2]	Azizi G, Keller JM, Lewis M, et al. Association of Hashimoto's thyroiditis with thyroid cancer[J]. Endocr Relat Cancer, 2014, 21(6): 845-852.
[3]	Antonelli A, Ferrari SM, Corrado A, et al. Autoimmune thyroid disorders[J]. Autoimmun Rev, 2015, 14(2): 174-180.
[4]	Dvorkin S, Robenshtok E, Hirsch D, et al. Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis[J]. J Clin Endocrinol Metab, 2013, 98(6): 2409-2414.
[5]	Xu S, Huang H, Qian J, et al. Prevalence of Hashimoto thyroiditis in adults with papillary thyroid cancer and its association with cancer recurrence and outcomes[J]. JAMA Netw Open, 2021, 4(7): e2118526.
[6]	Felicetti F, Catalano MG, Fortunati N. Thyroid autoimmunity and cancer[J]. Front Horm Res, 2017, 48: 97-109.
[7]	Pagano L, Mele C, Sama MT, et al. Thyroid cancer phenotypes in relation to inflammation and autoimmunity[J]. Front Biosci (Landmark Ed), 2018, 23(12): 2267-2282.
[8]	Guarino V, Castellone MD, Avilla E, et al. Thyroid cancer and inflammation[J]. Mol Cell Endocrinol, 2010, 321(1): 94-102.
[9]	Anderson NM, Simon MC. The tumor microenvironment[J]. Curr Biol, 2020, 30(16): R921-R925.
[10]	Muzza M, Degl'Innocenti D, Colombo C, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies[J]. Clin Endocrinol (Oxf), 2010, 72(5): 702-708.
[11]	Liotti F, Visciano C, Melillo RM. Inflammation in thyroid oncogenesis[J]. Am J Cancer Res, 2012, 2(3): 286-297.
[12]	Varricchi G, Loffredo S, Marone G, et al. The immune landscape of thyroid cancer in the context of immune checkpoint inhibition[J]. Int J Mol Sci, 2019, 20(16): 3934.
[13]	Visciano C, Liotti F, Prevete N, et al. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway[J]. Oncogene, 2015, 34(40): 5175-5186.
[14]	Pani F, Yasuda Y, Di Dalmazi G, et al. Pre-existing thyroiditis ameliorates papillary thyroid cancer: insights from a new mouse model[J]. Endocrinology, 2021, 162(10): bqab144.
[15]	Rotondi M, Coperchini F, Pignatti P, et al. Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: A first step toward a differentiation between autoimmune and tumor-related inflammation?[J]. J Clin Endocrinol Metab, 2013, 98(1): 308-313.
[16]	Ehlers M, Schott M. Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked?[J]. Trends Endocrinol Metab, 2014, 25(12): 656-664.
[17]	Borrello MG, Alberti L, Fischer A, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene[J]. Proc Natl Acad Sci U S A, 2005, 102(41): 14825-14830.
[18]	Russell JP, Shinohara S, Melillo RM, et al. Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors[J]. Oncogene, 2003, 22(29): 4569-4577.
[19]	Puxeddu E, Knauf JA, Sartor MA, et al. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response[J]. Endocr Relat Cancer, 2005, 12(2): 319-334.
[20]	Ralli M, Angeletti D, Fiore M, et al. Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation[J]. Autoimmun Rev, 2020, 19(10): 102649.
[21]	Sulaieva O, Chernenko O, Selesnov O, et al. Mechanisms of the impact of Hashimoto thyroiditis on papillary thyroid carcinoma progression: relationship with the tumor immune microenvironment[J]. Endocrinol Metab (Seoul), 2020, 35(2): 443-455.
[22]	Pan J, Ye F, Yu C, et al. Papillary Thyroid carcinoma landscape and its immunological link with Hashimoto thyroiditis at single-cell resolution[J]. Front Cell Dev Biol, 2021, 9: 758339.
[23]	Luo N, Nixon MJ, Gonzalez-Ericsson PI, et al. DNA methyltransferase inhibition upregulates MHC-Ⅰ to potentiate cytotoxic T lymphocyte responses in breast cancer[J]. Nat Commun, 2018, 9(1): 248.
[24]	Han LT, Hu JQ, Ma B, et al. IL-17A increases MHC class Ⅰ expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis[J]. Diagn Pathol, 2019, 14(1): 52.
[25]	Mandai M, Hamanishi J, Abiko K, et al. Dual faces of IFNγ in cancer progression: A role of PD-L1 induction in the determination of pro- and antitumor immunity[J]. Clin Cancer Res, 2016, 22(10): 2329-2334.
[26]	French JD, Kotnis GR, Said S, et al. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2012, 97(6): E934-E943.
[27]	Hu JQ, Lei BW, Wen D, et al. IL-2 enhanced MHC class Ⅰexpression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape in vitro[J]. J Cancer, 2020, 11(14): 4250-4260.
[28]	Lu ZW, Hu JQ, Liu WL, et al. IL-10 Restores MHC class Ⅰexpression and interferes with immunity in papillary thyroid cancer with Hashimoto thyroiditis[J]. Endocrinology, 2020, 161(10): bqaa062.
[29]	Hashemi Goradel N, Najafi M, Salehi E, et al. Cyclooxygenase-2 in cancer: A review[J]. J Cell Physiol, 2019, 234(5): 5683-5699.
[30]	Dong S, Xie XJ, Xia Q, et al. Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto's thyroiditis[J]. Am J Cancer Res, 2019, 9(8): 1786-1795.
[31]	Parvathareddy SK, Siraj AK, Annaiyappanaidu P, et al. Prognostic significance of COX-2 overexpression in BRAF-mutated middle eastern papillary thyroid carcinoma[J]. Int J Mol Sci, 2020, 21(24): 9498.
[32]	李中勇, 李乐. 桥本甲状腺炎合并甲状腺乳头状癌中环氧化酶-2、Survivin和胸腺基质淋巴细胞的表达及临床意义[J]. 中国耳鼻咽喉头颈外科, 2019, 26(6): 298-301.
[33]	Xu J, Ding K, Mu L, et al. Hashimoto's thyroiditis: A "double-edged sword" in thyroid carcinoma[J]. Front Endocrinol (Lausanne), 2022, 13: 801925.
[34]	Rotondi M, Groppelli G, Croce L, et al. Patients with chronic autoimmune thyroiditis are not at higher risk for developing clinically overt thyroid cancer: A 10-year follow-up study[J]. Eur J Endocrinol, 2020, 183(3): 317-323.
[35]	Brauner E, Gunda V, Vanden Borre P, et al. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer[J]. Oncotarget, 2016, 7(13): 17194-17211.
[36]	Cabanillas ME, Habra MA. Lenvatinib: role in thyroid cancer and other solid tumors[J]. Cancer Treat Rev, 2016, 42: 47-55.

Please choose a citation manager

Content to export